Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 3034701 Dose-finding Trial in Obesity or Overweight
NCT07662122Phase 2Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2026
- Primary completion
- Jun 2027
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of BI 3034701 in obesity (7 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Percentage change in body weight from baseline at 42 weeks. Started Jun 2026; status: active, not recruiting.
02
Drugs
BI 3034701
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07662122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07662122.